Literature DB >> 1752949

Photosensitized killing of cultured fibroblasts from patients with peroxisomal disorders due to pyrene fatty acid-mediated ultraviolet damage.

G Hoefler1, E Paschke, S Hoefler, A B Moser, H W Moser.   

Abstract

The influence of pyrene-fatty acids on the resistance of cells to ultraviolet (UV) radiation was investigated in cultured fibroblasts from patients with five types of peroxisomal disorders. All showed reduced survival compared to control. The effect varied with the biochemical defect involved and the chain length of the pyrene fatty acid. Reduced survival was observed in cells deficient in plasmalogens (rhizomelic chondrodysplasia punctata) and in cells deficient in peroxisomal fatty acid oxidation (bifunctional enzyme deficiency), which accumulated pyrene-fatty acids. X-linked adrenoleukodystrophy fibroblasts accumulated pyrene-fatty acids and showed increased UV sensitivity only when exposed to longer-chain pyrene fatty acids. UV radiation resistance was lowest in cells with combined impairment of plasmalogen synthesis and fatty acid oxidation (Zellweger syndrome, neonatal adrenoleukodystrophy), suggesting that UV sensitivity correlates inversely with the ratio of plasmalogens to radical producing substances. Fibroblasts deficient in plasmalogens gained normal UV resistance when their plasmalogen levels were normalized by hexadecylglycerol. UV resistance increased when Zellweger cells were fused with X-linked adrenoleukodystrophy cells, and also when Zellweger cells belonging to different complementation groups were fused. The results provide leads to the pathogenesis of the multiple malformations associated with peroxisomal disorders and a method for the selection of cells in which the metabolic defect has been corrected.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1752949      PMCID: PMC295755          DOI: 10.1172/JCI115509

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  26 in total

1.  Analysis of a human DNA excision repair gene involved in group A xeroderma pigmentosum and containing a zinc-finger domain.

Authors:  K Tanaka; N Miura; I Satokata; I Miyamoto; M C Yoshida; Y Satoh; S Kondo; A Yasui; H Okayama; Y Okada
Journal:  Nature       Date:  1990-11-01       Impact factor: 49.962

2.  A rapid method of total lipid extraction and purification.

Authors:  E G BLIGH; W J DYER
Journal:  Can J Biochem Physiol       Date:  1959-08

3.  Pyrene dodecanoic acid coenzyme A ester: peroxisomal oxidation and chain shortening.

Authors:  S Gatt; J Bremer; H Osmundsen
Journal:  Biochim Biophys Acta       Date:  1988-01-19

4.  A possible role for plasmalogens in protecting animal cells against photosensitized killing.

Authors:  R A Zoeller; O H Morand; C R Raetz
Journal:  J Biol Chem       Date:  1988-08-15       Impact factor: 5.157

5.  Cerebro-hepato-renal (Zellweger) syndrome, adrenoleukodystrophy, and Refsum's disease: plasma changes and skin fibroblast phytanic acid oxidase.

Authors:  A Poulos; P Sharp; A J Fellenberg; D M Danks
Journal:  Hum Genet       Date:  1985       Impact factor: 4.132

6.  Peroxisomal disorders: complementation analysis using beta-oxidation of very long chain fatty acids.

Authors:  M C McGuinness; A B Moser; H W Moser; P A Watkins
Journal:  Biochem Biophys Res Commun       Date:  1990-10-15       Impact factor: 3.575

7.  Genetic and phenotypic heterogeneity in disorders of peroxisome biogenesis--a complementation study involving cell lines from 19 patients.

Authors:  A A Roscher; S Hoefler; G Hoefler; E Paschke; F Paltauf; A Moser; H Moser
Journal:  Pediatr Res       Date:  1989-07       Impact factor: 3.756

8.  Adrenoleukodystrophy: impaired oxidation of fatty acids due to peroxisomal lignoceroyl-CoA ligase deficiency.

Authors:  O Lazo; M Contreras; A Bhushan; W Stanley; I Singh
Journal:  Arch Biochem Biophys       Date:  1989-05-01       Impact factor: 4.013

9.  Peroxisomal fatty acid beta-oxidation in relation to the accumulation of very long chain fatty acids in cultured skin fibroblasts from patients with Zellweger syndrome and other peroxisomal disorders.

Authors:  R J Wanders; C W van Roermund; M J van Wijland; R B Schutgens; J Heikoop; H van den Bosch; A W Schram; J M Tager
Journal:  J Clin Invest       Date:  1987-12       Impact factor: 14.808

10.  Neonatal seizures and retardation in a girl with biochemical features of X-linked adrenoleukodystrophy: a possible new peroxisomal disease entity.

Authors:  S Naidu; G Hoefler; P A Watkins; W W Chen; A B Moser; S Hoefler; N E Rance; J M Powers; M Beard; W R Green
Journal:  Neurology       Date:  1988-07       Impact factor: 9.910

View more
  12 in total

1.  Synthesis and antioxidant properties of an unnatural plasmalogen analogue bearing a trans O-vinyl ether linkage.

Authors:  Ravi S Lankalapalli; Joseph T Eckelkamp; Debajit Sircar; David A Ford; Papasani V Subbaiah; Robert Bittman
Journal:  Org Lett       Date:  2009-07-02       Impact factor: 6.005

2.  Plasmalogens and oxidative stress: evidence against a major role of plasmalogens in protection against the superoxide anion radical.

Authors:  G A Jansen; R J Wanders
Journal:  J Inherit Metab Dis       Date:  1997-03       Impact factor: 4.982

3.  A novel method for determining peroxisomal fatty acid β-oxidation.

Authors:  Masashi Morita; Shun Matsumoto; Airi Okazaki; Kaito Tomita; Shiro Watanabe; Kosuke Kawaguchi; Daishiro Minato; Yuji Matsuya; Nobuyuki Shimozawa; Tsuneo Imanaka
Journal:  J Inherit Metab Dis       Date:  2016-06-20       Impact factor: 4.982

Review 4.  Biochemistry of peroxisomes in health and disease.

Authors:  I Singh
Journal:  Mol Cell Biochem       Date:  1997-02       Impact factor: 3.396

5.  Mitochondrial alterations caused by defective peroxisomal biogenesis in a mouse model for Zellweger syndrome (PEX5 knockout mouse).

Authors:  E Baumgart; I Vanhorebeek; M Grabenbauer; M Borgers; P E Declercq; H D Fahimi; M Baes
Journal:  Am J Pathol       Date:  2001-10       Impact factor: 4.307

Review 6.  Mammalian peroxisomes and reactive oxygen species.

Authors:  Michael Schrader; H Dariush Fahimi
Journal:  Histochem Cell Biol       Date:  2004-07-08       Impact factor: 4.304

7.  Novel subtype of peroxisomal acyl-CoA oxidase deficiency and bifunctional enzyme deficiency with detectable enzyme protein: identification by means of complementation analysis.

Authors:  Y Suzuki; N Shimozawa; S Yajima; S Tomatsu; N Kondo; Y Nakada; S Akaboshi; M Lai; Y Tanabe; T Hashimoto
Journal:  Am J Hum Genet       Date:  1994-01       Impact factor: 11.025

8.  Oxidation of pristanic acid in fibroblasts and its application to the diagnosis of peroxisomal beta-oxidation defects.

Authors:  B C Paton; P C Sharp; D I Crane; A Poulos
Journal:  J Clin Invest       Date:  1996-02-01       Impact factor: 14.808

9.  Resistance to erucic acid as a selectable marker for peroxisomal activity: isolation of revertants of an infantile Refsum disease cell line.

Authors:  E Bachir Bioukar; F Straehli; K H Ng; M O Rolland; T Hashimoto; J P Carreau; J Deschatrette
Journal:  J Inherit Metab Dis       Date:  1994       Impact factor: 4.982

Review 10.  From peroxisomal disorders to common neurodegenerative diseases - the role of ether phospholipids in the nervous system.

Authors:  Fabian Dorninger; Sonja Forss-Petter; Johannes Berger
Journal:  FEBS Lett       Date:  2017-09-07       Impact factor: 4.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.